Om

Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing patient-friendly treatments for lysosomal storage disorders, a group of rare inherited diseases with significant unmet medical need. The company’s current programs center on non-invasive small molecule therapies and a gene therapy candidate designed to address the underlying biology of these disorders. Its pipeline includes orally available approaches aimed at supporting lysosome function, reducing neuroinflammation, and improving neuronal survival, alongside an intranasal gene therapy candidate intended for use in combination strategies. Polaryx Therapeutics concentrates on rare pediatric and orphan disease markets, with development efforts targeting conditions such as neuronal ceroid lipofuscinosis, Krabbe disease, Sandhoff disease, and Niemann-Pick diseases. Founded in 2014 and headquartered in Paramus, New Jersey, Polaryx Therapeutics plays a specialized role in the biotechnology sector by advancing therapies for underserved rare disease populations.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I POLARYX THERAPEUTICS MED ENDAVU: Køb Polaryx Therapeutics ($1V8) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Polaryx Therapeutics, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.